Výsledky vyhledávání - "Kelly S. Klega"

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

Autor: Peter Anderson, Maurizio Ghisoli, Brian D. Crompton, Kelly S. Klega, Leonard H. Wexler, Emily K. Slotkin, Laura Stanbery, Luisa Manning, Gladice Wallraven, Meghan Manley, Staci Horvath, Ernest Bognar, John Nemunaitis

Publikováno v: Clinical Cancer Research. 29:1689-1697

Purpose: Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell therapy expressing bi-shRNA furin/GMCSF plasmid, which previously demonstrated monotherapy activity in advanced ES. Herein

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dabd853eb193c233f8a96470bdf13b21
https://doi.org/10.1158/1078-0432.ccr-22-2292

Zobrazit plný text záznamu

Data from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

Autor: John Nemunaitis, Ernest Bognar, Staci Horvath, Meghan Manley, Gladice Wallraven, Luisa Manning, Laura Stanbery, Emily K. Slotkin, Leonard H. Wexler, Kelly S. Klega, Brian D. Crompton, Maurizio Ghisoli, Peter Anderson

Background:Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell therapy expressing bi-shRNA furin/GMCSF plasmid, which previously demonstrated monotherapy activity in advanced ES. Here

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e9c17819c5c38aa589d9eacee45a4a2
https://doi.org/10.1158/1078-0432.c.6533209.v2

Zobrazit plný text záznamu

supplementary table 1 from Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

supplementary table

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d446a4970956e0103abfff81aab4cc2
https://doi.org/10.1158/1078-0432.22490743.v1

Zobrazit plný text záznamu

Supplementary Table from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Autor: Ewa Sicinska, George D. Demetri, Anthony Letai, Suzanne George, Chandrajit P. Raut, Brian D. Crompton, Morgan R. Benson, Kelly S. Klega, Jessica L. Andersen, Elizaveta Lavrova, Leona A. Doyle, Madeleine L. Taddei, Justin A. Anderson, Michael A. Loycano, Patrick Bhola, Matthew L. Hemming

Supplementary Table from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d14dbb91f4e7590044f3aade67c8d08
https://doi.org/10.1158/1078-0432.22488117

Zobrazit plný text záznamu

Supplementary Figure from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Supplementary Figure from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37300001c59cec0c8be4c3658314bb53
https://doi.org/10.1158/1078-0432.22488129

Zobrazit plný text záznamu

Supplementary Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Supplementary Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503cfd081509776cc6a5fa7cb8f6570d
https://doi.org/10.1158/1078-0432.22488138

Zobrazit plný text záznamu

Data from Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Purpose:Leiomyosarcoma (LMS) is a neoplasm characterized by smooth muscle differentiation, complex copy-number alterations, tumor suppressor loss, and the absence of recurrent driver mutations. Clinical management for advanced disease relies on the u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01dd589b849808d448e1a45d6a1c5a84
https://doi.org/10.1158/1078-0432.c.6532647

Zobrazit plný text záznamu

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Autor: Matthew L. Hemming, Patrick Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson, Brian D. Crompton, Chandrajit P. Raut, Suzanne George, Anthony Letai, George D. Demetri, Ewa Sicinska

Publikováno v: Clin Cancer Res

Purpose: Leiomyosarcoma (LMS) is a neoplasm characterized by smooth muscle differentiation, complex copy-number alterations, tumor suppressor loss, and the absence of recurrent driver mutations. Clinical management for advanced disease relies on the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e40fc35cd195e6506ae25d5d9a351601
https://doi.org/10.1158/1078-0432.ccr-21-3523

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání